Hussain Al Rand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hussain Al Rand has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Abdulmohsen Alterki
Department of Otolaryngology, Head and Neck Surgery, Zain and Al Sabah Hospital, Ministry of Health, Kuwait City, Kuwait
1 shared publication Ahmed Mohd Haider Alamadi
Al Kuwait Hospital, MoH, Dubai, United Arab Emirates
1 shared publication- Asma Fikri
Public Health Sector , Ministry of Health and Prevention, P.O. Box 1853, Dubai , UAE
1 shared publication Ayman Ali Fraihat
Sulaiman Al Habib Hospital, Dubai, United Arab Emirates
1 shared publication- Fatima Alshehhi
Public Health Sector , Ministry of Health and Prevention, P.O. Box 1853, Dubai , UAE
1 shared publication - Habiba Alsafar
Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, UAE
1 shared publication
Latest Publications
- Open Access
- 4 March 2022
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 29 (6)
Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the UAE
The UAE implemented swift and proactive mitigation measures to combat the COVID-19 pandemic. While there are currently five primary approved vaccines in the UAE, inactivated vaccine BBIBP-CorV (Sinopharm), which has a 78% effectiveness in preventing hospitalization due to COVID-19 infections, 1 and mRNA vaccine BNT162b2 (Pfizer-BioNTech), with an effectiveness at 93% in preventing hospitalization due to COVID-19 infections, 2 are most commonly administered. Due to the successful early COVID-19 vaccination rollout, ~91.6% of the population has been vaccinated, which is mainly attributed to a model governance system, logistical capabilities, accessibility and delivery, digital infrastructure and vaccine manufacturing facility. 3
- 4 March 2022
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 29 (6)
Open AccessSimilar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the UAE
The UAE implemented swift and proactive mitigation measures to combat the COVID-19 pandemic. While there are currently five primary approved vaccines in the UAE, inactivated vaccine BBIBP-CorV (Sinopharm), which has a 78% effectiveness in preventing hospitalization due to COVID-19 infections, 1 and mRNA vaccine BNT162b2 (Pfizer-BioNTech), with an effectiveness at 93% in preventing hospitalization due to COVID-19 infections, 2 are most commonly administered. Due to the successful early COVID-19 vaccination rollout, ~91.6% of the population has been vaccinated, which is mainly attributed to a model governance system, logistical capabilities, accessibility and delivery, digital infrastructure and vaccine manufacturing facility. 3
- Open Access
- 1 January 2022
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 15, 1-12
Expert Opinion on Biological Treatment of Chronic Rhinosinusitis with Nasal Polyps in the Gulf Region
Chronic rhinosinusitis (CRS) is defined as the inflammation of nose and paranasal sinuses, affecting the patients’ quality of life and productivity. Chronic rhinosinusitis with nasal polyps (CRSwNP) is a principal clinical entity confirmed by the existence of chronic sinonasal inflammation and is characterized by anterior or posterior rhinorrhea, nasal congestion, hyposmia and/or facial pressure or facial pain. Several epidemiologic studies have revealed wide variations in the incidence of CRS among regions globally ranging from 4.6% to 12%. The Gulf countries are also witnessing an unprecedented burden of CRSwNP. According to the current clinical guidelines, glucocorticosteroids and antibiotics are the principal pharmacotherapeutic approaches. Endoscopic sinus surgery is recommended for those who have failed maximal pharmacotherapy. Recently, biologics are considered as an alternative best approach due to the complications associated with medical therapy and surgery. However, precise data on the clinical position of biologic agents in the management of CRSwNP in the Gulf region is not available. The present review article addresses the current diagnostic and management approaches for CRSwNP and also emphasizes the role of emerging biologics in the current treatment strategies for CRSwNP in the Gulf region. Further, a consensus protocol was convened to rationalize the guideline recommendations, strategize the best practices with biologics, and develop clinical practice guidelines for all primary-care specialists in the Gulf region. The consensus-based report will be a useful reference tool for primary-care physicians in primary-healthcare settings, regarding the appropriate time for the initiation of biological treatment in the Gulf region.
- 1 January 2022
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 15, 1-12
Open AccessExpert Opinion on Biological Treatment of Chronic Rhinosinusitis with Nasal Polyps in the Gulf Region
Chronic rhinosinusitis (CRS) is defined as the inflammation of nose and paranasal sinuses, affecting the patients’ quality of life and productivity. Chronic rhinosinusitis with nasal polyps (CRSwNP) is a principal clinical entity confirmed by the existence of chronic sinonasal inflammation and is characterized by anterior or posterior rhinorrhea, nasal congestion, hyposmia and/or facial pressure or facial pain. Several epidemiologic studies have revealed wide variations in the incidence of CRS among regions globally ranging from 4.6% to 12%. The Gulf countries are also witnessing an unprecedented burden of CRSwNP. According to the current clinical guidelines, glucocorticosteroids and antibiotics are the principal pharmacotherapeutic approaches. Endoscopic sinus surgery is recommended for those who have failed maximal pharmacotherapy. Recently, biologics are considered as an alternative best approach due to the complications associated with medical therapy and surgery. However, precise data on the clinical position of biologic agents in the management of CRSwNP in the Gulf region is not available. The present review article addresses the current diagnostic and management approaches for CRSwNP and also emphasizes the role of emerging biologics in the current treatment strategies for CRSwNP in the Gulf region. Further, a consensus protocol was convened to rationalize the guideline recommendations, strategize the best practices with biologics, and develop clinical practice guidelines for all primary-care specialists in the Gulf region. The consensus-based report will be a useful reference tool for primary-care physicians in primary-healthcare settings, regarding the appropriate time for the initiation of biological treatment in the Gulf region.